Pliant Therapeutics Announces Appointment of David Pyott to Board of Directors
January 12 2021 - 8:00AM
Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage
biopharmaceutical company focused on discovering and developing
novel therapies for the treatment of fibrosis, today announced the
appointment of Dr. David Pyott, former Chairman and Chief Executive
Officer of Allergan, to Pliant’s Board of Directors.
“David is an accomplished international
pharmaceutical executive whose extensive experience in building
companies will be invaluable at this stage of Pliant’s
development,” said Bernard Coulie, M.D., Ph.D., President and Chief
Executive Officer of Pliant. “It is my great pleasure to welcome
David to the Board and look forward to his insights as we advance
and expand our clinical stage portfolio.”
Dr. Pyott joins the Pliant Board of Directors with
more than 30 years of executive leadership and management
experience within the global pharmaceutical industry. Dr. Pyott
most recently served as Chairman and Chief Executive Offer of
Allergan, where, over his 17-year tenure in this role, he
transformed the company from a small eye care business with $1
billion in annual sales into a global specialty pharmaceutical and
medical device company with 2014 annual sales of over $7 billion.
Prior to Allergan, Dr. Pyott held the role of Head of the Novartis
Nutrition Division and served as a member of the Executive
Committee of Switzerland-based Novartis AG.
“I am excited to be joining the Pliant board and
supporting an accomplished group of board members and a strong
leadership team to help guide the company’s mission of delivering
innovative and potential transformative treatments to patients,”
said Dr. Pyott. “I believe Pliant’s novel approach has the
potential to address the need for new treatments for fibrotic
diseases.”
In addition to Pliant, Dr. Pyott currently serves
as a member of the Board of Directors of Alnylam Pharmaceuticals
and BioMarin Pharmaceutical, as Chairman of Bioniz Therapeutics,
Inc., a private biotechnology company, and is a member of the
Supervisory Board of Royal Philips in the Netherlands, a public
diversified health technology company. Dr. Pyott serves as Deputy
Chairman of the Governing Board of the London Business School,
President of the Ophthalmology Foundation, President of the
Advisory Board of the American Academy of Ophthalmology and is also
a Trustee of the California Institute of Technology.
Dr. Pyott holds a Diploma in International and
European Law from the Europa Institute at the University of
Amsterdam, an Honorary Degree in Medicine and a Master of Arts
degree from the University of Edinburgh, and a Master of Business
Administration degree from the London Business School.
About Pliant Therapeutics,
Inc. Pliant Therapeutics is a clinical stage
biopharmaceutical company focused on discovering and developing
novel therapies for the treatment of fibrosis. Pliant's lead
product candidate, PLN-74809, is an oral small-molecule dual
selective inhibitor of avß6 and avß1 integrins that is in
development for the treatment of idiopathic pulmonary fibrosis, or
IPF, and primary sclerosing cholangitis, or PSC. PLN-74809 has
received Orphan Drug Designation from the U.S. Food and Drug
Administration for both IPF and PSC. Pliant is currently
recruiting Phase 2a trials of PLN-74809 for the treatment of IPF
and PSC. Pliant's second product candidate, PLN-1474, is a
small-molecule selective inhibitor of avß1 for the treatment
of liver fibrosis associated with nonalcoholic steatohepatitis, or
NASH, which Pliant has partnered with Novartis. PLN-1474 is
currently undergoing a Phase 1 trial. In addition to clinical stage
programs, Pliant currently has two preclinical programs targeting
oncology and muscular dystrophies. For additional information
about Pliant Therapeutics,
visit www.pliantrx.com and follow us
on Twitter, LinkedIn, and Facebook.
Investor Contact: Christopher
Keenan Vice President, Investor Relations and Corporate
Communications Pliant Therapeutics, Inc. ir@pliantrx.com
Media Contact: Cambria Fuqua
Canale Communications cambria.fuqua@canalecomm.com
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/95826a4d-80dc-482a-aab1-c8684bfa48e5
Pliant Therapeutics (NASDAQ:PLRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Pliant Therapeutics (NASDAQ:PLRX)
Historical Stock Chart
From Apr 2023 to Apr 2024